Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico

The Breast - Tập 24 - Trang 218-223 - 2015
Cynthia Villarreal-Garza1,2,3, Enrique Soto-Perez-de-Celis4, Erika Sifuentes1, Santiago Ruano1, Berenice Baez-Revueltas1, Fernando Lara-Medina1, Claudia Arce-Salinas1, Alberto Alvarado-Miranda1, Yanin Chavarri-Guerra4, Claudia Caro-Sanchez1, Noel Castañeda-Soto1, Enrique Bargallo-Rocha1, Alejandro Mohar1,2
1Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico
2Unit of Biomedical Investigation in Cancer, National Autonomous University of Mexico and National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico
3Breast Cancer Center, Instituto Tecnológico de Monterrey, Eugenio Garza Sada Sur 2501, Tecnológico, 64849 Monterrey, NL, Mexico
4Department of Hemato/Oncology, National Institute of Medical Science and Nutrition, Vasco de Quiroga 15, Sección XVI, Tlalpan, Ciudad de México, Distrito Federal, Mexico

Tài liệu tham khảo

Haile, 2012, A review of cancer in U.S. Hispanic populations, Cancer Prev Res, 5, 150, 10.1158/1940-6207.CAPR-11-0447

American Cancer Society, 2012

Chávarri-Guerra, 2012, Breast cancer in Mexico: a growing challenge to health and the health system, Lancet Oncol, 13, e335, 10.1016/S1470-2045(12)70246-2

Patel, 2010, Breast cancer in latinas: gene expression, differential response to treatments, and differential toxicities in latinas compared with other population groups, Oncologist, 15, 466, 10.1634/theoncologist.2010-0004

Banegas, 2014, Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California, Breast Cancer Res Treat, 144, 625, 10.1007/s10549-014-2882-1

Hudis, 2007, Trastuzumab–mechanism of action and use in clinical practice, N Engl J Med, 357, 39, 10.1056/NEJMra043186

Chavez-Macgregor, 2010, Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity, Cancer, 116, 4168, 10.1002/cncr.25296

Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101

Gianni, 2011, Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial, Lancet Oncol, 12, 236, 10.1016/S1470-2045(11)70033-X

Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122

Buzdar, 2005, Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676, 10.1200/JCO.2005.07.032

Buzdar, 2007, Clin Cancer Res, 13, 228, 10.1158/1078-0432.CCR-06-1345

Gianni, 2010, Lancet, 375, 377, 10.1016/S0140-6736(09)61964-4

Untch, 2010, Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study, J Clin Oncol, 28, 2024, 10.1200/JCO.2009.23.8451

Untch, 2011, Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, 29, 3351, 10.1200/JCO.2010.31.4930

von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595

Kaufmann, 2007, Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006, Ann Oncol, 18, 1927, 10.1093/annonc/mdm201

Rastogi, 2008, Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27, J Clin Oncol, 26, 778, 10.1200/JCO.2007.15.0235

Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3

Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9

Cortazar, 2014, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 384, 164, 10.1016/S0140-6736(13)62422-8

Kim, 2013, Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer, Ann Oncol, 24, 1999, 10.1093/annonc/mdt131

Alvarado-Cabrero, 2009, Ruíz E.,Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings, Ann Diagn Pathol, 13, 151, 10.1016/j.anndiagpath.2009.02.003

Arce-Salinas, 2012, Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico, Rev Invest Clin, 64, 7

Castro-Sánchez, 2013, Breast cancer outcomes after implementation of “Seguro popular” at the National Institute of Medical Sciences and Nutrition, Salvador Zubirán (INCMNSZ), Mexico city, Mexico

Howlader, 2013

Mohar, 2009, Available resources for the treatment of breast cancer in Mexico, Salud Publica Mex, 51, s263

Thông tin
Thông tin xuất bản

The Breast

Tập 24

218-223

Thông tin tác giả